If you would like to request a PDF for any of the below Research in Addiction Medicine Scholars (RAMS) published papers, please contact Jules Canfield, Program Manager, at


Bach P, Ti L, Hayashi K, Cui Z, Milloy MJ, Fairbairn N. Trends in cocaine and crystal methamphetamine injection over time in a Canadian setting between 2008 and 2018. J Subst Use Addict Treat. 2023;151:208982. PMID: 36848997.

Bahji A, Acion L, Laslett AM, Adinoff B. Exclusion of the non-English-speaking world from the scientific literature: Recommendations for change for addiction journals and publishers. Nordisk Alkohol Nark. 2023;40(1):6-13. PMCID: PMC9893128.

Brothers TD, Walley AY, Rivers-Bowerman H, McLeod M, Genge L. Grayken lessons: between a rock and a hard place? A 37-year-old man with acute liver injury while enrolled in a managed alcohol program for severe alcohol use disorder. Addict Sci Clin Pract. 2023;18(1):14. PMCID: PMC9988200

Friedmann PD, Jawa R, Wilson D, Ramsey SE, Hoskinson R Jr, McKenzie M, Walley AY, Green TC, Bratberg J, Rich JD. Prescribe to Save Lives: An Intervention to Increase Naloxone Prescribing Among HIV Clinicians. J Addict Med. 2023;17(5):598-603. PMCID: PMC10593983.

Habersham LL. An unexpected path to addiction medicine. Am J Obstet Gynecol MFM. 2023;5(3):100849. PMCID: PMC9974569.

Harvey LH, Branch-Elliman W, Boudreau J, Sliwinski SK, Gifford AL, Ho MQ, Dinges E, Hyde J. Harm reduction stories: leveraging graphic medicine to engage veterans in substance use services within the VA. Harm Reduct J. 2023;20(1):177. PMCID: PMC10702088.

Harvey L, Kimmel SD, Edelman EJ. Meeting the moment: More infectious disease physicians must be prepared to provide buprenorphine. Clin Infect Dis. 2023;76(7):1205-1208. PMID: 36695340.

Harvey LH, Sliwinski SK, Flike K, Boudreau J, Gifford AL, Branch-Elliman W, Hyde J. The integration of harm reduction services in the Veterans Health Administration (VHA): A qualitative analysis of barriers and facilitators. J Addict Dis. 2023:1-9. PMCID: PMC10630529.

Ibrahim C, Tang VM, Blumberger DM, Malik S, Tyndale RF, Trevizol AP, Barr MS, Daskalakis ZJ, Zangen A, Le Foll B. Efficacy of insula deep repetitive transcranial magnetic stimulation combined with varenicline for smoking cessation: A randomized, double-blind, sham controlled trial. Brain Stimul. 2023;16(5):1501-1509. PMID: 37806524.

Kleinman RA. Overdose Deaths Among Non-Hispanic American Indian and Alaska Native Individuals in the US: 1999-2020. J Gen Intern Med. 2023;38(7):1762-1764. PMCID: PMC10212896.

Kleinman RA, Sanches M. Methadone-involved overdose deaths in the United States before and during the COVID-19 pandemic. Drug Alcohol Depend. 2023;242:109703. PMCID: PMC9674402.

Lewer D, Brothers TD, Croxford S, Desai M, Emanuel E, Harris M, Hope VD. Opioid Injection-Associated Bacterial Infections in England, 2002-2021: A Time Series Analysis of Seasonal Variation and the Impact of Coronavirus Disease 2019. Clin Infect Dis. 2023;77(3):338-345. PMCID: PMC10425189.

Lewer D, Brothers TD, Harris M, Rock KL, Copeland CS. Opioid-related deaths during hospital admissions or shortly after discharge in the United Kingdom: A thematic framework analysis of coroner reports. PLoS One. 2023;18(4):e0283549. PMCID: PMC10115296.

McFadden R, Wallace-Keeshen S, Petrillo Straub K, Hosey RA, Neuschatz R, McNulty K, Thakrar AP. Xylazine-associated Wounds: Clinical Experience From a Low-barrier Wound Care Clinic in Philadelphia. J Addict Med. 2023. Epub ahead of print. PMID: 38019592.

Nolan S, Fairgrieve C, Dong H, Garrod E, van Heukelom H, Parappilly BP, McLean M, Tsui JI, Samet JH. A Hospital-based Managed Alcohol Program in a Canadian Setting. J Addict Med. 2023;17(2):190-196. PMCID: PMC10062701.

Peterkin AF, Jawa R, Menezes K, You J, Cabral H, Ruiz-Mercado G, Park TW, Kehoe J, Taylor JL, Weinstein ZM. Pre-paid phone distribution: A tool for improving healthcare engagement for people with substance use disorder. Subst Use Misuse. 2023;58(4):585-589. PMCID: PMC10557432.

Simon CB, McCabe CJ, Matson TE, Oliver M, Bradley KA, Hallgren KA. High test-retest reliability of the Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) questionnaire completed by primary care patients in routine care. Alcohol Clin Exp Res (Hoboken). 2023. Epub ahead of print. PMID: 38099421.

Tang VM, Goud R, Zawertailo L, Selby P, Coroiu A, Sloan ME, Chenoweth MJ, Buchman D, Ibrahim C, Blumberger DM, Foll BL. Repetitive transcranial magnetic stimulation for smoking cessation: Next steps for translation and implementation into clinical practice. Psychiatry Res. 2023;326:115340. PMID: 37454610.

Tang VM, Ibrahim C, Rodak T, Goud R, Blumberger DM, Voineskos D, Le Foll B. Managing substance use in patients receiving therapeutic repetitive transcranial magnetic stimulation: A scoping review. Neurosci Biobehav Rev. 2023;155:105477. PMID: 38007879.

Tang VM, Yu D, Weissman CR, Jones BDM, Wang G, Sloan ME, Blumberger DM, Daskalakis ZJ, Le Foll B, Voineskos D. Treatment outcomes in major depressive disorder in patients with comorbid alcohol use disorder: A STAR*D analysis. J Affect Disord. 2023;339:691-697. PMCID: PMC10496139.

Thakrar AP, Faude S, Perrone J, Milone MC, Lowenstein M, Snider CK, Spadaro A, Delgado MK, Nelson LS, Kilaru AS. Association of Urine Fentanyl Concentration With Severity of Opioid Withdrawal Among Patients Presenting to the Emergency Department. J Addict Med. 2023;17(4):447-453. PMCID: PMC10440418.

Thakrar AP, Pytell JD, Stoller KB, Walters V, Weiss RD, Chander G. Transitioning off methadone: A qualitative study exploring why patients discontinue methadone treatment for opioid use disorder. J Subst Use Addict Treat. 2023;150:209055. PMCID: PMC10330232.

Thakrar AP, Uritsky TJ, Christopher C, Winston A, Ronning K, Sigueza AL, Caputo A, McFadden R, Olenik JM, Perrone J, Delgado MK, Lowenstein M, Compton P. Safety and preliminary outcomes of short-acting opioid agonist treatment (sOAT) for hospitalized patients with opioid use disorder. Addict Sci Clin Pract. 2023;418(1):13. PMCID: PMC9951406.


Appa A, Adamo M, Le S, Davis J, Winston L, Doernberg SB, Chambers H, Martin M, Hills NK, Coffin PO, Jain V. Comparative 1-year outcomes of invasive Staphylococcus aureus infections among persons with and without drug use: An observational cohort study. Clin Infect Dis. 2022;74(2):263-270. PMCID: PMC8800187.

Appa A, Adamo M, Le S, Davis J, Winston L, Doernberg SB, Chambers H, Martin M, Hills NK, Coffin P, Jain V. Patient-directed discharges among persons who use drugs hospitalized with invasive Staphylococcus aureus infections: Opportunities for improvement. Am J Med. 2022;135(1):91-96. PMID: 34508704

Bahji A, Bach P, Danilewitz M, Crockford D, El-Guebaly N, Devoe DJ, Saitz R. Comparative efficacy and safety of pharmacotherapies for alcohol withdrawal: a systematic review and network meta-analysis. Addiction. 2022;117(10):2591-2601. PMCID: PMC9969997.

Bahji A, Bach P, Danilewitz M, Crockford D, Devoe DJ, El-Guebaly N, Saitz R. Pharmacotherapies for adults with alcohol use disorders: A systematic review and network meta-analysis. J Addict Med. 2022;16(6):630-638. PMCID: PMC10010623.

Bahji A, Brothers TD, Danilewitz M. Considering Cannabis Use in Differential Diagnosis: A Teachable Moment. JAMA Intern Med. 2022;182(1):66-67. PMCID: PMC8881091.

Bahji A, Crockford D, El-Guebaly N. Management of post-acute alcohol withdrawal: A mixed-studies scoping review. J Stud Alcohol Drugs. 2022;83(4):470-479. PMCID: PMC9798381.

Bahji A, Danilewitz M, Maser B, Guerin E, Frank E. Association between substance use and professional outcomes among medical students: Findings from a Canadian cross-sectional survey. Can J Addict. 2022;13(4):32-43. PMCID: PMC10353729.

Bahji A, Milloy MJ, Bach P, Sociás ME. Challenges and opportunities for further research involving the cannabis-to-opioid use transition. Addiction. 2022;117(10):2752-2754. PMCID: PMC9949991.

Bahji A, Zarate CA, Vazquez GH. Efficacy and safety of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. Expert Opin Drug Saf. 2022;21(6):853-866. PMCID: PMC9949988.

Brothers TD, Fraser J, MacAdam E, Morgan B, Webster D. Uptake of slow-release oral morphine as opioid agonist treatment among hospitalised patients with opioid use disorder. Drug Alcohol Rev. 2022;41(2):430-434. PMCID: PMC8814044.

Brothers TD, Leaman M, Bonn M, Lewer D, Atkinson J, Fraser J, Gillis A, Gniewek M, Hawker L, Hayman H, Jorna P, Martell D, O’Donnell T, Rivers-Bowerman H, Genge L. Evaluation of an emergency safe supply drugs and managed alcohol program in COVID-19 isolation hotel shelters for people experiencing homelessness. Drug Alcohol Depend. 2022;235:109440. PMCID: PMC8988445.

Brothers TD, Lewer D, Jones N, Colledge-Frisby S, Farrell M, Hickman M, Webster D, Hayward A, Degenhardt L. Opioid agonist treatment and risk of death or rehospitalization following injection drug use-associated bacterial and fungal infections: A cohort study in New South Wales, Australia. PLoS Med. 2022;19(7):e1004049. PMCID: PMC9295981.

Brothers TD, Mosseler K, Kirkland S, Melanson P, Barrett L, Webster D. Unequal access to opioid agonist treatment and sterile injecting equipment among hospitalized patients with injection drug use-associated infective endocarditis. PLoS One. 2022;17(1):e0263156. PMCID: PMC8791472.

Ferguson M, Medley A, Rittenbach K, Brothers TD, Strike C, Ng J, Leece P, Elton-Marshall T, Ali F, Lorenzetti DL, Buxton JA. Priority setting for Canadian take-home naloxone best practice guideline development: an adapted online Delphi method. Harm Reduct J. 2022;19(1):71. PMCID: PMC9250272.

Harris MTH, Laks J, Stahl N, Bagley SM, Saia K, Wechsberg WM. Gender dynamics in substance use and treatment: A women’s focused approach. Med Clin North Am. 2022;106(1):219-234. PMCID: PMC8881090.

Jawa R, Stein MD, Anderson B, Liebschutz JM, Stewart C, Phillips KT, Barocas JA. Behavioral risk factors for HIV infection in hospitalized persons who co-use stimulants and opioids. AIDS Behav. 2022;26(4):1047-1055. PMCID: PMC8435119.

Jawa R, Murray S, Tori M, Bratberg J, Walley A. Federal policymakers should urgently and greatly expand naloxone access. Am J Public Health. 2022;112(4):558-561. PMCID: PMC8961838.

Jawa R, Walley AY, Wilson DJ, Green TC, McKenzie M, Hoskinson R Jr, Bratberg J, Ramsey S, Rich JD, Friedmann PD. Prescribe to save lives: Improving buprenorphine prescribing among HIV clinicians. J Acquir Immune Defic Syndr. 2022;90(5):546-552. PMCID: PMC9283214.

Jawa R, Laks J, Saravanan N, Demers L, Wishik-Miller G. Physician trainees’ compassion satisfaction, burnout, and self-efficacy when caring for people who inject drugs. Subst Abus. 2022;43(1):675-681. PMID: 34666627

Jawa R, Rozansky H, Clemens D, Fagan M, Walley AY. Rethinking home-based outpatient parenteral antibiotic therapy for persons who inject drugs: An opportunity for change in the time of COVID-19. J Addict Med. 2022;16(2):e70-e72. PMCID: PMC8501142.

Klaire S, Janssen RM, Olson K, Bridgeman J, Korol EE, Chu T, Ghafari C, Sabeti S, Buxton JA, Lysyshyn M. Take-home drug checking as a novel harm reduction strategy in British Columbia, Canada. Int J Drug Policy. 2022;106:103741. PMCID: PMC9970175

Kleinman RA, Nielsen S, Weiss RD. Is daily supervised buprenorphine-naloxone dosing necessary? BMJ. 2022;378:e071467. PMID: 35973725.

Kleinman RA, Weiss RD. Benzodiazepine-involved overdose deaths in the USA: 2000-2019. J Gen Intern Med. 2022;37(8):2103-2109. PMCID: PMC9198172.

Kleinman RA, Sanches M. Impacts of eliminating audio-only care on disparities in telehealth accessibility. J Gen Intern Med. 2022;37(15):4021-4023. PMCID: PMC8999992.

Kleinman RA, Brothers TD, Danilewitz M, Bahji A. Office-based methadone prescribing for opioid use disorder: the Canadian model. J Addict Med. 2022;16(5):499-504. PMCID: PMC9271524.

Kimmel SD, Rosenmoss S, Bearnot B, Weinstein Z, Yan S, Walley AY, Larochelle MR. Northeast postacute medical facilities disproportionately reject referrals for patients with opioid use disorder. Health Aff (Millwood). 2022;41(3):434-444. PMCID: PMC10775137. 

Levander XA, Pytell JD, Stoller KB, Korthuis PT, Chander G. COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership. Subst Abus. 2022;43(1):633-639. PMCID: PMC8810732.

Levander XA, Wheelock H, Pope J, Lee A, Hartmann K, Abuelkhair S, Gregg JL, Buchheit BM. Low-threshold buprenorphine via community partnerships and telemedicine- Case reports of expanding access to addiction treatment during COVID-19. J Addict Med. 2022;16(1):e56-e58. PMCID: PMC8815644.

Morford KL, Tetrault JM, Zhou B, Li F, Gleeson B, Edelman EJ, Stein MD, Barry DT, Madden L. The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study. Drug Alcohol Depend. 2022;241:109707. PMCID: PMC9777057.

Nolan S, Kelian S, Kerr T, Young S, Malmgren I, Ghafari C, Harrison S, Wood E, Lysyshyn M, Holliday E. Harm reduction in the hospital: An overdose prevention site (OPS) at a Canadian hospital. Drug Alcohol Depend. 2022;239:109608. PMCID: PMC9970047.

Pytell JD, Thakrar AP, Chander G, Colantuoni E. Changes in alcohol consumption by beverage type attributable to the COVID-19 pandemic for 10 states, March 2020 to November 2020: An ecological simulation-based analysis. J Addict Med. 2022;16(6):e412-e416. PMCID: PMC9653060.

Shearer D, Young S, Fairbairn N, Brar R. Challenges with buprenorphine inductions in the context of the fentanyl overdose crisis: A case series. Drug Alcohol Rev. 2022;41(2):444-448. PMCID: PMC8926080.

Thakrar AP. Short-acting opioids for hospitalized patients with opioid use disorder. JAMA Intern Med. 2022;182(3):247-248. PMID: 35099508

Thakrar AP, Kleinman RA. Opioid withdrawal management in the fentanyl era. Addiction. 2022;117(9):2560-2561. PMID: 35373864.

Touesnard N, Brothers TD, Bonn M, Edelman EJ. Overdose deaths and HIV infections among people who use drugs: shared determinants and integrated responses. Expert Rev Anti Infect Ther. 2022;20(8):1061-1065. PMCID: PMC10693947.

Wang A, Jawa R, Mackin S, Whynott L, Buchholz C, Childs E, Bazzi AR. “We were building the plane as we were flying it, and we somehow made it to the other end”: syringe service program staff experiences and well-being during the COVID-19 pandemic. Harm Reduct J. 2022;19(1):78. PMCID: PMC9284956.

Zolopa C, Brothers TD, Leclerc P, Mary JF, Morissette C, Bruneau J, Hyshka E, Martin NK, Larney S. Changes in supervised consumption site use and emergency interventions in Montréal, Canada in the first twelve months of the COVID-19 pandemic: An interrupted time series study. Int J Drug Policy. 2022;110:103894. PMCID: PMC9574459.


Brothers TD, Fraser J, Webster D. Caring for people who inject drugs when they are admitted to hospital. CMAJ. 2021;193(12):E423-E424. PMCID: PMC8096383

Brothers TD, Kaulbach J, Tran A. Unhealthy alcohol use in a 65-year-old man awaiting surgery. CMAJ. 2021;193(32):E1250-E1252. PMCID: PMC8386484.

Brothers TD, Lewer D, Bonn M, Webster D, Harris M. Social and structural determinants of injecting-related bacterial and fungal infections among people who inject drugs: protocol for a mixed studies systematic review. BMJ Open. 2021;11(8):e049924. PMCID: PMC8354281.

Brothers TD, Lewer D, Thakrar AP. Linking opioid use disorder treatment from hospital to community. Addiction. 2021;116(8):2244-2245. PMCID: PMC8511949

De Aquino JP, Flores JM, Avila-Quintero VJ, Compton P, Sofuoglu M. Pharmacological treatment of pain among persons with opioid addiction: A systematic review and meta-analysis with implications for drug development. Addict Biol. 2021;26(4):e12964. PMID: 3297499

De Aquino JP, Parida S, Sofuoglu M. The pharmacology of buprenorphine microinduction for opioid use disorder. Clin Drug Investig. 2021;41(5):425-436. PMCID: PMC8020374

Harris MTH, Bagley SM, Maschke A, Schoenberger SF, Sampath S, Walley AY, Gunn CM. Competing risks of women and men who use fentanyl: “The number one thing I worry about would be my safety and number two would be overdose.” J Subst Abuse Treat. 2021;125:108313. PMCID: PMC8140193 

Harris MTH, Peterkin A, Bach P, Englander H, Lapidus E, Rolley T, Weimer MB, Weinstein ZM. Adapting inpatient addiction medicine consult services during the COVID-19 pandemic. Addict Sci Clin Pract. 2021;16(1):13. PMCID: PMC7903401

Harris MT, Seliga RK, Fairbairn N, Nolan S, Walley AY, Weinstein ZM, Turnbull J. Outcomes of Ottawa, Canada’s Managed Opioid Program (MOP) where supervised injectable hydromorphone was paired with assisted housing. Int J Drug Policy. 2021;98:103400. PMCID: PMC8881087.

Jawa R, Saravanan N, Burrowes SAB, Demers L. A call for training graduate medical students on harm reduction for people who inject drugs. Subst Abus. 2021;42(3):266-268. PMID: 34086530

Jawa R, Stein MD, Anderson B, Liebschutz JM, Stewart C, Phillips KT, Barocas JA. Association of skin infections with sharing of injection drug preparation equipment among people who inject drugs. Int J Drug Policy. 2021;94:103198. PMCID: PMC8373634 

Kimmel SD, Rosenmoss S, Bearnot B, Larochelle M, Walley AY. Rejection of patients with opioid use disorder referred for post-acute medical care before and after an anti-discrimination settlement in Massachusetts. J Addict Med. 2021;15(1), 20–26. PMCID: PMC7859880 

Labonté LE, Young S. High-dose intravenous hydromorphone for patients who use opioids in the hospital setting: time to reduce the barriers. Harm Reduct J. 2021;18(1):87. PMCID: PMC8361239.

Levander XA, Vega TA, Seaman A, Korthuis T, Englander H. Exploring how hospitalization can alter hepatitis c virus treatment prioritization and trajectories in people who use drugs: A qualitative analysis. Subst Abus. 2022;43(1):245-252. PMCID: PMC8695635

Levander XA, Vega TA, Seaman A, Korthuis PT, Englander H. Utilising an access to care integrated framework to explore the perceptions of hepatitis C treatment of hospital-based interventions among people who use drugs. Int J Drug Policy. 2021;96:103356. PMCID: PMC8568624.

Lewer D, Eastwood B, White M, Brothers TD, McCusker M, Copeland C, Farrell M, Petersen I. Fatal opioid overdoses during and shortly after hospital admissions in England: A case-crossover study. PLoS Med. 2021;18(10):e1003759. PMCID: PMC8491890.

Pytell JD, Sklar MD, Carrese J, Rastegar DA, Gunn C, Chander G. “I’m a survivor”: Perceptions of chronic disease and survivorship among individuals in long-term remission from opioid use disorder. J Gen Intern Med. 2021;37(3):593-600. PMCID: PMC8141362

Roy PJ, Price R, Choi S, Weinstein ZM, Bernstein E, Cunningham CO, Walley AY. Shorter outpatient wait-times for buprenorphine are associated with linkage to care post-hospital discharge. Drug Alcohol Depend. 2021;224:108703. PMCID: PMC8180499

Tang VM, Le Foll B, Blumberger DM, Voineskos D. Repetitive Transcranial Magnetic Stimulation for Comorbid Major Depressive Disorder and Alcohol Use Disorder. Brain Sci. 2021;12(1):48. PMCID: PMC8773947.

Vega TA, Levander XA, Seaman A, Korthuis T, Englander H. “Sobriety equals getting rid of hepatitis C”: A qualitative study exploring the interplay of substance use disorder and hepatitis C among hospitalized adults. J Subst Abuse Treat. 2021;37(3):593-600.PMCID: PMC8217723

Young S, Hayashi K, Grant C, Milloy MJ, DeBeck K, Wood E, Fairbairn N. Buprenorphine/naloxone associated with a reduced odds of fentanyl exposure among a cohort of people who use drugs in Vancouver, Canada. Drug Alcohol Depend. 2021 Nov 1;228:109006. PMCID: PMC8812726.


Appa A, Rowe C, Hessol NA, Coffin P. Beyond overdose: Drug-related deaths in people with and without HIV in San Francisco, 2007-2018. Open Forum Infect Dis. 2020;7(12), ofaa565. PMCID: PMC7757430

Bach P, Hayashi K, Milloy MJ, Nosova E, Kerr T, Wood E, Fairbairn N. Characterising the increasing prevalence of crystal methamphetamine use in Vancouver, Canada, from 2006-2017: A gender-based analysisDrug Alcohol Rev. 2020;39(7):932-940. PMCID: PMC7683370

Calcaterra SL, Binswanger IA, Edelman EJ, McNair BK, Wakeman SE, O’Connor PG. The impact of access to addiction specialist on attitudes, beliefs and hospital-based opioid use disorder related care: A survey of hospitalist physicians. Subst Abus. 2020;1–9. PMCID: PMC7541600 

Harris M, Joseph K, Hoeppner B, Wachman EM, Gray JR, Saia K, Wakeman S, Blair-Merritt MH, Schiff DM. A retrospective cohort study examining the utility of perinatal urine toxicology testing to guide breastfeeding initiation. J Addict Med. 2021;15(4):311-317. PMCID: PMC8044259 

Joudrey PJ, Chadi N, Roy P, Morford KL, Bach P, Kimmel S, Wang EA, Calcaterra SL. Pharmacy-based methadone dispensing and drive time to methadone treatment in five states within the United States: A cross-sectional study. Drug Alcohol Depend. 2020;211:107968. PMCID: PMC7529685

Kim JH, Fine DR, Li L, Kimmel SD, Ngo LH, Suzuki J, Price CN, Ronan MV, Herzig SJ. Disparities in United States hospitalizations for serious infections in patients with and without opioid use disorder: A nationwide observational study. PLoS Med. 2020;17(8), e1003247. PMCID: PMC7413412

Kimmel S, Bach P, Walley AY. Comparison of treatment options for refractory opioid use disorder in the United States and Canada: a narrative review. J Gen Intern Med. 2020;35(8):2418-2426. PMCID: PMC7403280 

Kimmel SD, Miller NS. The clinical microbiology laboratory and the opioid epidemic: Challenges and opportunities. Infect Dis Clin of North Am. 2020;34(3), 465–478. PMCID: PMC7428057

Kimmel SD, Walley AY, Linas BP, Kalesan B, Awtry E, Dobrilovic N, White L, LaRochelle M. Effect of publicly reported aortic valve surgery outcomes on valve surgery in injection drug- and non-injection drug-associated endocarditis. Clin Infect Dis. 2020;71(3):480-487. PMCID: PMC7384313

Komaromy M, Harris M, Koenig RM, Tomanovich M, Ruiz-Mercado G, Barocas JA. “Caring for COVID’s most vulnerable victims: A safety-net hospital responds.” Res Sq. 2020; PMCID: PMC7605557

Manhapra A, Stefanovics E, Rosenheck R. Initiating opioid agonist treatment for opioid use disorder nationally in the Veterans Health Administration: Who gets what? Subst Abus. 2020;41(1):110-120. PMID: 31403914

Roy PJ, Choi S, Bernstein E, Walley AY. Appointment wait-times and arrival for patients at a low-barrier access addiction clinic. J Subst Abuse Treat. 2020;114, 108011. PMID: 32527508


Bach P, Hartung D. Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders. Addict Sci Clin Pract. 2019;14(1):30. PMCID: PMC6717996

Bozinoff N, Luo L, Dong H, Krüsi A, DeBeck K. Street-involved youth engaged in sex work at increased risk of syringe sharing. AIDS Care. 2019; 31(1):69-76. PMCID: PMC6250570

Calcaterra SL, Bach P, Chadi A, Chadi N, Kimmel SD, Morford KL, Roy P, Samet JH. Methadone matters: What the United States can learn from the global effort to treat opioid addiction. J Gen Intern Med2019; 10.1007/s11606-018-4801-3. PMCID: PMC6544670

Dean A, Kimmel S. Free trade and opioid overdose death in the United States. SSM Popul Health. 2019;8:100409. PMCID: PMC6606896

Manhapra A, Chakraborty A, Arias AJ. Topiramate pharmacotherapy for alcohol use disorder and other addictions: A narrative review. J Addict Med. 2019;13(1):7-22. PMID: 30096077

Pytell JD, Buresh ME, Graddy R. Outcomes of a novel office-based opioid treatment program in an internal medicine resident continuity practice. Addict Sci Clin Pract. 2019;14(1):46. PMCID: PMC6921403

Vaezazizi LM, Campbell ANC, Pavlicova M, Hu MC, Nunes EV. Understanding site variability in a multisite clinical trial of a technology-delivered psychosocial intervention for substance use disorders. J Subst Abuse Treat. 2019;105:64-70. PMCID: PMC8459398


Bagley SM, Cheng DM, Winter M, Alford DP, LaBelle C, Walley AY, Samet JH. Opioid and cocaine use among primary care patients on buprenorphine-Self-report and urine drug testsDrug Alcohol Depend. 2018; 192:245-249. PMCID: PMC6291245

Bone CW, Goodfellow AM, Vahidi M, Gelberg L. Prevalence of sexual violence and its association with depression among male and female patients with risky drug use in urban federally qualified health centersJ Urban Health. 2018; 95(1): 111-115. PMCID: PMC5862699

Bozinoff N, Anderson BJ, Bailey GL, Stein MD. Correlates of stigma severity among persons seeking opioid detoxification. J Addict Med. 2018; 12(1):19-23. PMCID: PMC5786480

Chang DC, Klimas J, Wood E, Fairbairn N. A case of opioid overdose and subsequent death after medically supervised withdrawal: The problematic role of rapid tapers for opioid use disorder. 2018; 12(1):80-83. PMCID: PMC5786466

Jun JH, Fairbairn N. Integrating injectable opioid agonist treatment into a drug treatment court program: A case studySubst Abus. 2018; 39(4): 493-496. PMCID: PMC6750900

Klimas J, Dong H, Fairbairn N, Socías E, Barrios R, Wood E, Kerr T, Montaner J, Milloy MJ. Eligibility for heroin-assisted treatment (HAT) among people who inject opioids and are living with HIV in a Canadian settingAddict Sci Clin Pract. 2018; 13(1):3. PMCID: PMC5812056

Lundsberg LS, Peglow S, Qasba N, Yonkers KA, Gariepy AM. Is preconception substance use associated with unplanned or poorly timed pregnancy?J Addict Med. 2018; 12(4): 321-328. PMCID: PMC6066412

Manhapra A, Agbese E, Leslie DL, Rosenheck RA. Three-year retention in buprenorphine treatment for opioid use disorder among privately insured adults. Psychiatr Serv. 2018;69(7):768-776. PMID: 29656707

Manhapra A, Arias AJ, Ballantyne JC. The conundrum of opioid tapering in long-term opioid therapy for chronic pain: A commentarySubst Abus. 2018;39(2):152-161. PMCID: PMC6129223

Peglow SL, Binswanger IA. Preventing opioid overdose in the clinic and hospital: Analgesia and opioid antagonistsMed Clin North Am. 2018; 102(4):621-634. PMCID: PMC6029888

Weinstein ZM, Gryczynski G, Cheng DM, Quinn E, Hui D, Kim HW, Labelle C, Samet JH. Tapering off and returning to buprenorphine maintenance in a primary care office based addiction treatment (OBAT) programDrug Alcohol Depend. 2018; 189:166-171. PMCID: PMC6139651


Bozinoff N, Small W, Long C, DeBeck K, Fast D. Still “at risk”: An examination of how street-involved young people understand, experience, and engage with “harm reduction” in Vancouver’s inner cityInt J Drug Policy. 2017; 45:33-39. PMCID: PMC5576444

Bozinoff N, Wood E, Dong H, Richardson L, Kerr T, DeBeck K. Syringe sharing among a prospective cohort of street-involved youth: Implications for needle distribution programsAIDS Behav. 2017; 21(9):2717-2725. PMCID: PMC5640474

Fairbairn N, Wood E, Dobrer S, Dong H, Kerr T, Debeck K. The relationship between hazardous alcohol use and violence among street-involved youthAm J Addict. 2017; 26(8):852-858. PMCID: PMC5730057

Fairbairn NS, Walley AY, Cheng DM, Quinn E, Bridden C, Chaisson C, Blokhina E, Lioznov D, Krupitsky E, Raj A, Samet JH. Mortality in HIV-infected alcohol and drug users in St.Petersburg, RussiaPLoS One. 2017; 11(11):e0166539. PMCID: PMC5127495

Hui D, Weinstein ZM, Cheng DM, Quinn E, Kim H, Labelle C, Samet JH. Very early disengagement and subsequent re-engagement in primary care office based opioid treatment (OBOT) with buprenorphineJ Subst Abuse Treat. 2017; 79:12-19. PMCID: PMC5522736

Lévesque A, Campbell AN, Pavlicova M, Hu MC, Walker R, McClure EA, Ghitza UE, Bailey G, Stitzer M, Nunes EV. Coping strategies as a mediator of internet-delivered psychosocial treatment: Secondary analysis from a NIDA CTN multisite effectiveness trialAddict Behav. 2017; 65:74-80. PMCID: PMC5483182

Lin LA, Bohnert ASB, Jannausch M, Goesling J, Ilgen MA. Use of non-pharmacological strategies for pain relief in addiction treatment patients with chronic painAm J Addict. 2017; 26(6):564-567. PMCID: PMC5576866

Manhapra A, Rosenheck R. Tobacco use disorder among patients with smoking-related chronic medical disease: Association with comorbid substance use disordersJ Addict Med. 2017; 11(4):293-299. PMCID: PMC 5537028

Nolan S, Walley AY, Heeren TC, Patts GJ, Ventura AS, Sullivan MM, Samet JH, Saitz R. HIV-infected individuals who use alcohol and other drugs, and virologic suppressionAIDS Care. 2017; 29(9):1129-1136. PMCID: PMC5543330

Weinstein ZM, Cheng DM, Quinn E, Hui D, Kim H, Gryczynski G, Samet JH. Psychoactive medications and disengagement from office based opioid treatment (OBOT) with buprenorphineDrug Alcohol Depend. 2017; 170:9-16. PMCID: PMC5183557

Weinstein ZM, Kim HW, Cheng DM, Quinn E, Hui D, Labelle CT, Drainoni ML, Bachman SS, Samet JH. Long-term retention in office based opioid treatment with buprenorphineJ Subst Abuse Treat. 2017; 74:65-70. PMCID: PMC5312773


Lévesque A, Roy É, Jutras-Aswad D, Zang G, Artenie AA, Bruneau J. Examining the link between psychological distress, mental health disorders and sharing behaviors among cocaine usersAddict Behav. 2016; 62:54-9. PMID: 28103534

Manhapra A, Quinones L, Rosenheck R. Characteristics of veterans receiving buprenorphine vs. methadone for opioid use disorder nationally in the Veterans Health AdministrationDrug Alcohol Depend. 2016; 160:82-9. PMCID: PMC4767635

Mortazavi BJ, Downing NS, Bucholz EM, Dharmarajan K, Mahapra A, Li SX, Negahban SN, Krumholz HM. Analysis of machine learning techniques for heart failure readmissionsCirc Cardiovasc Qual Outcomes. 2016; 9(6):629-640. PMCID: PMC5459389

Stein MD, Kanabar M, Anderson BJ, Lembke A, Bailey GL. Reasons for benzodiazepine use among persons seeking opioid detoxificationJ Subst Abuse Treat. 2016; 68:57-61. PMCID: PMC4955948

Wilder CM, Miller SC, Tiffany E, Winhusen T, Winstanley EL, Stein MD. Risk factors for opioid overdose and awareness of overdose risk among veterans prescribed chronic opioids for addiction or painJ Addict Dis. 2016; 35(1):42-51. PMCID: PMC4751580


Bagley SM, Peterson J, Cheng DM, Jose C, Quinn E, O’Connor PG, Walley AY. Overdose education and naloxone rescue kits for family members of individuals who use opioids: Characteristics, motivations, and naloxone useSubst Abus. 2015; 36(2):149-54. PMCID: PMC4809347

Manhapra A, Stefanovics E, Rosenheck R. Treatment outcomes for veterans with PTSD and substance use: Impact of specific substances and achievement of abstinenceDrug Alcohol Depend. 2015; 156:70-77. PMCID: PMC4633308

Park TW, Cheng DM, Samet JH, Winter MR, Saitz R. Chronic care management for substance dependence in primary care among patients with co-occurring disordersPsychiatr Serv. 2015; 66(1):72-9. PMCID: PMC4282827

Tofighi B, Grossman E, Buirkle E, McNeely J, Gourevitch M, Lee JD. Mobile phone use patterns and preferences in safety net office-based buprenorphine patientsJ Addict Med. 2015; 9(3):217-21. PMCID: PMC4693598


Bagley SM, Wachman EM, Holland E, Brogly SB. Review of the assessment and management of neonatal abstinence syndromeAddict Sci Clin Pract. 2014; 9(1):19. PMCID: PMC4166410

Nolan S, Dias Lima V, Fairbairn N, Kerr T, Montaner J, Grebely J, Wood E. The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug usersAddiction. 2014; 109(12):2053-9. PMCID: PMC4229435

Park TW, Bohnert AS, Austin KL, Saitz R, Pizer SD. Datapoints: regional variation in benzodiazepine prescribing for patients on opioid agonist therapyPsychiatr Serv. 2014; 65(1):4. PMCID: PMC5697151